CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
4.385
-0.175 (-3.84%)
Apr 2, 2026, 1:34 PM EDT - Market open
CytomX Therapeutics Employees
CytomX Therapeutics had 69 employees as of December 31, 2025. The number of employees decreased by 52 or -42.98% compared to the previous year.
Employees
69
Change (1Y)
-52
Growth (1Y)
-42.98%
Revenue / Employee
$1,104,362
Profits / Employee
-$295,217
Market Cap
947.94M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 69 | -52 | -42.98% | 69 | 0 |
| Dec 31, 2024 | 121 | -1 | -0.82% | 119 | 2 |
| Dec 31, 2023 | 122 | 4 | 3.39% | 120 | 2 |
| Dec 31, 2022 | 118 | -60 | -33.71% | 116 | 2 |
| Dec 31, 2021 | 178 | 32 | 21.92% | 174 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Xeris Biopharma Holdings | 435 |
| UroGen Pharma | 291 |
| KalVista Pharmaceuticals | 275 |
| Xencor | 260 |
| Geron | 258 |
| uniQure | 221 |
| MapLight Therapeutics | 133 |
| Inhibrx Biosciences | 110 |
CTMX News
- 15 days ago - Why Is CytomX Therapeutics Stock Falling On Wednesday? - Benzinga
- 15 days ago - CytomX Therapeutics: Great News, But Early Data Do Not Quite Justify This Price Level - Seeking Alpha
- 15 days ago - CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 16 days ago - CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 16 days ago - CytomX: The Probody Mask Just Slipped, And Investors Like What They See (Upgrade) - Seeking Alpha
- 17 days ago - Mid-Cap CytomX Therapeutics' Colorectal Cancer Data Fuels Stock Rally - Benzinga
- 17 days ago - CytomX Therapeutics, Inc. (CTMX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 17 days ago - CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update - GlobeNewsWire